A vs. ABBV: Agilent vs. AbbVie Stock Comparison

November 11, 2026

How do Agilent (A) and AbbVie (ABBV) stack up? This page sets them side by side across company profile, performance and risk, profitability, growth, financial strength, dividends, and valuation, with selected fundamentals also measured against each stock's industry-group peers.

Company Profile

Agilent (A) and AbbVie (ABBV) both fall under the Pharmaceuticals, Biotechnology & Life Sciences industry group, but A is classified in Life Sciences Tools & Services while ABBV is classified in Biotechnology.

Company profile comparison for Agilent (A) and AbbVie (ABBV)
Profile Item	A	ABBV
Name	AgileThought, Inc. Class A Common Stock	AbbVie Inc.
Country/Region	United States	United States
GICS Sector	Health Care	Health Care
GICS Industry Group	Pharmaceuticals, Biotechnology & Life Sciences	Pharmaceuticals, Biotechnology & Life Sciences
GICS Industry	Life Sciences Tools & Services	Biotechnology
GICS Sub-Industry	Life Sciences Tools & Services	Biotechnology
Market Capitalization	49.28 billion USD	514.92 billion USD
Currency	USD	USD
Exchange	NYSE	NYSE
Listing Date	November 18, 1999	January 2, 2013
Security Type	Common Stock	Common Stock

Price Performance

Cumulative Growth

ABBV

GSPC

Agilent (A) vs. AbbVie (ABBV), with S&P 500 (GSPC) for reference: Growth of a $10,000 investment over the past five years. Adjusted for dividends and splits.

Trailing Returns

Loading price history…

Trailing total returns for Agilent (A) and AbbVie (ABBV). Returns over one year are annualized.

Calendar-Year Returns

Loading price history…

Calendar-year total returns for Agilent (A) and AbbVie (ABBV). Each bar is that year's total return, measured year-end to year-end.

Performance Metrics

Price performance metrics for Agilent (A) and AbbVie (ABBV)
Metric	A	ABBV
Total Return (1Y)	22.92%	37.33%
Total Return (3Y, Annualized)	19.33%	32.74%
Total Return (5Y, Annualized)	3.03%	24.73%

Risk Profile

Drawdown History

ABBV

GSPC

Agilent (A) vs. AbbVie (ABBV), with S&P 500 (GSPC) for reference: Drawdown from the running peak over the past five years. Each line shows the decline from its prior peak; 0% marks a new high.

Return Distribution

Loading price history…

Distribution of monthly total returns for Agilent (A) and AbbVie (ABBV). Each bar is the share of months whose return fell in that 5% bucket.

Risk Metrics

Risk profile metrics for Agilent (A) and AbbVie (ABBV)
Metric	A	ABBV
Volatility (1Y, Annualized)	33.10%	25.65%
Beta (5Y)	1.22	0.21
Max Drawdown (5Y)	-38.09%	-21.92%
Avg. Volume (3M)	2.25M	4.76M

Risk-Adjusted Performance

Risk-Return Positioning

A and ABBV are plotted by 1-year volatility (risk) and 1-year return. The dashed Capital Allocation Line runs from the risk-free rate through the shared industry median.

Risk-Adjusted Metrics

Risk-adjusted metrics for Agilent (A) and AbbVie (ABBV)
Metric	A	ABBV
Sharpe Ratio (1Y)	0.56	1.29
Sortino Ratio (1Y)	0.96	2.02

Profitability

ROE (TTM)

Capital efficiency shows on one side only: Agilent (A) earns 20.97% on shareholders’ equity, ranked against its industry; AbbVie (ABBV) has no ROE this period.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

20.97%

Max: 109.18%
A: 20.97%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 109.18%
Q3: 6.23%
Median: -26.66%
Q1: -64.05%
Min: -167.77%
ABBV: --

Agilent (A) vs. AbbVie (ABBV): ABBV does not report ROE, so it has no value marker; A is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Net Margin (TTM)

Agilent (A) at 19.53% keeps the most of each sales dollar — above its industry’s net margin range — and AbbVie (ABBV) at 15.67% also retains a top-quartile share.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.53%

A: 19.53%
Max: 18.05%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

15.67%

Max: 18.05%
ABBV: 15.67%
Q3: 4.78%
Median: 0.00%
Q1: -4.14%
Min: -17.05%

Agilent (A) vs. AbbVie (ABBV): A comparison of their net margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Operating Margin (TTM)

Both Agilent (A) at 25.56% and AbbVie (ABBV) at 39.59% convert sales into operating profit at a top-quartile rate, pointing to tighter cost discipline before financing and tax.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

25.56%

Max: 83.12%
A: 25.56%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

39.59%

Max: 83.12%
ABBV: 39.59%
Q3: 14.77%
Median: 0.00%
Q1: -78.82%
Min: -207.40%

Agilent (A) vs. AbbVie (ABBV): A comparison of their operating margin against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Profitability Metrics

Profitability metrics for Agilent (A) and AbbVie (ABBV)
Metric	A	ABBV
ROE (TTM)	20.97%	--
ROA (TTM)	8.63%	10.74%
Net Margin (TTM)	19.53%	15.67%
Operating Margin (TTM)	25.56%	39.59%
Gross Margin (TTM)	53.65%	73.72%

Growth

Revenue Growth

Both Agilent (A) at 6.73% and AbbVie (ABBV) at 8.57% land near their industries' usual revenue growth ranges, so top-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. AbbVie (ABBV): A comparison of their Revenue Growth across different time periods.

EPS Growth

Both Agilent (A) at 3.16% and AbbVie (ABBV) at -0.84% land near their industries' usual EPS growth ranges, so bottom-line momentum looks broadly in line with peers on both sides.

Agilent (A) vs. AbbVie (ABBV): A comparison of their EPS Growth across different time periods.

Growth Metrics

Growth metrics for Agilent (A) and AbbVie (ABBV)
Metric	A	ABBV
Revenue Growth (YoY)	6.73%	8.57%
Revenue Growth (3Y CAGR)	0.48%	1.75%
EPS Growth (YoY)	3.16%	-0.84%
EPS Growth (3Y CAGR)	3.02%	-29.03%

Financial Strength

Current Ratio (MRQ)

Both Agilent (A) at 2.05 and AbbVie (ABBV) at 0.87 run current ratio in the tighter-liquidity quartile of industry peers, leaving thinner cushions against current liabilities than typical competitors.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.05

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
A: 2.05
Min: 0.10

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.87

Max: 25.13
Q3: 12.13
Median: 5.52
Q1: 2.47
ABBV: 0.87
Min: 0.10

Agilent (A) vs. AbbVie (ABBV): A comparison of their current ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Debt / Equity (MRQ)

Only one side’s leverage can be read here: Agilent (A) carries debt-to-equity ratio of 0.56 against its industry range, while AbbVie (ABBV) reports no figure this period.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.56

Max: 1.42
Q3: 0.65
A: 0.56
Median: 0.15
Q1: 0.02
Min: 0.00

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

Max: 1.42
Q3: 0.65
Median: 0.15
Q1: 0.02
Min: 0.00
ABBV: --

Agilent (A) vs. AbbVie (ABBV): ABBV does not report debt-to-equity ratio, so it has no value marker; A is benchmarked against the Pharmaceuticals, Biotechnology & Life Sciences industry group.

Financial Strength Metrics

Financial strength metrics for Agilent (A) and AbbVie (ABBV)
Metric	A	ABBV
Current Ratio (MRQ)	2.05	0.87
Debt / Equity (MRQ)	0.56	--
Net Debt / EBITDA	1.15	2.21

Dividends

Dividend Yield (TTM)

Both Agilent (A) at 0.59% and AbbVie (ABBV) at 2.40% yield above their industries’ entire benchmark ranges — high enough that dividend safety, not income, becomes the first question.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

0.59%

A: 0.59%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

2.40%

ABBV: 2.40%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. AbbVie (ABBV): A comparison of their dividend yield against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Payout Ratio (TTM)

AbbVie (ABBV) reports payout ratio above 100% at 117.35%, meaning dividends exceeded current-period earnings and sustainability needs extra context. Meanwhile Agilent (A) reports 19.98%, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

19.98%

A: 19.98%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

117.35%

ABBV: 117.35%
Max: 0.00%
Q3: 0.00%
Median: 0.00%
Q1: 0.00%
Min: 0.00%

Agilent (A) vs. AbbVie (ABBV): A comparison of their payout ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Dividend Metrics

Dividend metrics for Agilent (A) and AbbVie (ABBV)
Metric	A	ABBV
Dividend Yield (TTM)	0.59%	2.40%
Dividend Payout Ratio (TTM)	19.98%	117.35%

Valuation

P/E Ratio (TTM)

Agilent (A) at 34.47 is near its industry’s usual P/E ratio, while AbbVie (ABBV) at 50.05 sits in the richer quartile — ABBV needs stronger growth or earnings quality to justify the premium.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

34.47

Max: 85.34
Q3: 43.46
A: 34.47
Median: 26.69
Q1: 13.30
Min: 0.07

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

50.05

Max: 85.34
ABBV: 50.05
Q3: 43.46
Median: 26.69
Q1: 13.30
Min: 0.07

Agilent (A) vs. AbbVie (ABBV): A comparison of their P/E ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/S Ratio (TTM)

On P/S ratio, both Agilent (A) at 6.68 and AbbVie (ABBV) at 7.80 are priced roughly in line with their industries — neither looks cheap nor rich on a sales basis.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.68

Max: 58.18
Q3: 25.77
Median: 7.30
A: 6.68
Q1: 3.01
Min: 0.01

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

7.80

Max: 58.18
Q3: 25.77
ABBV: 7.80
Median: 7.30
Q1: 3.01
Min: 0.01

Agilent (A) vs. AbbVie (ABBV): A comparison of their P/S ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

P/B Ratio (MRQ)

AbbVie (ABBV) reports a negative P/B ratio of -112.34, meaning negative book equity — the multiple itself is not meaningful for valuation. Meanwhile Agilent (A) reports 6.69, ranking against industry peers normally.

A

Pharmaceuticals, Biotechnology & Life Sciences industry group

6.69

Max: 13.53
A: 6.69
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59

ABBV

Pharmaceuticals, Biotechnology & Life Sciences industry group

-112.34

Max: 13.53
Q3: 6.54
Median: 3.25
Q1: 1.69
Min: -5.59
ABBV: -112.34

Agilent (A) vs. AbbVie (ABBV): A comparison of their P/B ratio against the Pharmaceuticals, Biotechnology & Life Sciences industry group benchmark.

Valuation Metrics

Valuation metrics for Agilent (A) and AbbVie (ABBV)
Metric	A	ABBV
P/E Ratio (TTM)	34.47	50.05
P/S Ratio (TTM)	6.68	7.80
P/B Ratio (MRQ)	6.69	-112.34
Free Cash Flow Yield (TTM)	2.15%	3.44%